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Introduction: Few data are available on the epidemiology of interstitial lung diseases (ILDs),
especially after the current classification of idiopathic interstitial pneumonias. The aim of this
study is to provide data on the epidemiology of ILDs in Greece, under the ATS/ERS interna-
tional consensus.
Methods: Departments of Pneumonology were contacted and asked to complete a question-
naire for every case of ILD that was alive on 2004 as well as for every new case from 1st January
2004 to 31st December 2004. Questions on the patients’ demographic data, the exact diagnosis
and the procedures used to establish the diagnosis were included. Centers covering about 60%
of the Greek population have been analyzed.
Results: A total of 967 cases have been registered. The estimated prevalence of ILDs is 17.3 cases
per 100,000 inhabitants. The estimated annual incidence of ILDs is 4.63 new cases per 100,000
inhabitants. The most frequent disease is sarcoidosis (34.1%), followed in decreasing order by
idiopathic pulmonary fibrosis (19.5%), ILD associated with collagen vascular diseases (12.4%),
cryptogenic organizing pneumonia (5.3%), histiocytosis (3.8%), and hypersensitivity pneumonitis
(2.6%). Unclassified ILD or not otherwise specified accounted for the 8.5% of prevalent cases.al ERS Congress, Copenhagen 2005.
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Epidemiology of interstitial lung diseases 1123Conclusions: These data suggest that sarcoidosis and idiopathic pulmonary fibrosis are the most
frequent ILDs in our population. In comparison with the few previous reports, interesting dissim-
ilarities have been observed.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
More than 200 different entities are included under the term
interstitial lung diseases (ILDs). In their pathogenesis many
factors such as environmental and occupational agents,
infections, drugs, radiation and genetic predisposition have
been implicated.1e4 However, themajority of these diseases
are considered idiopathic, without a curable treatment.5
Several attempts to estimate the incidence and prevalence
of ILDs, although limited by variable and confusing diagnostic
criteria, suggest that there is a rising trend in ratesworldwide
aswell as international differences in the prevalence rates of
the various forms of ILDs.6e12 The recent American Thoracic
Society/European Respiratory Society [ATS/ERS] interna-
tional consensus classification of the idiopathic interstitial
pneumonias, offers an opportunity for greater precision in
epidemiological studies.1e3
There are few epidemiologic studies available regarding
the incidence, prevalence or relative frequency of ILDs.6e18
To date, a number of ILD registries have been established in
various regions. Apart from the case of New Mexico,6 the
other registries have been organized by pneumonologists,
and clearly underestimate the real incidence and preva-
lence of ILDs.9e18 However, knowledge of the relative
frequency of the diagnosis of the different types of ILD may
provide interesting information about these diseases.
Furthermore, histopathologic subsets of idiopathic inter-
stitial pneumonias (IIPs) have prognostic significance.19e21
The aim of this study is to estimate the prevalence and
incidence rate of ILDs in Greece in the light of the new
international consensus classification of the IIPs and to
compare our findings with those of other reports.Materials and methods
By the end of 2003 the Interstitial Lung diseases Group of
the Hellenic Thoracic Society (HILD) contacted the
departments of pneumonology with special interest in ILDs
from all over Greece and asked pneumonologists to
complete a questionnaire for every case of ILD that was
alive on 2004 (prevalent case) as well as for every new case
(incident case) diagnosed from 1st January 2004 to 31st
December 2004.
In order to achieve a good response rate the questionnaire
was kept as simple as possible (one-page, Appendix A).
Questions on the patients’ demographic data, the exact
diagnosis-type of ILD and the procedures, such as high-reso-
lution computed tomography (HRCT), bronchoalveolar
lavage (BAL), transbronchial lungbiopsy, surgical lungbiopsy,
and serology, used to establish the diagnosis were included.
In every participating center the expert pneumonologist
on ILDs was responsible to identify the cases based on the
actual histological and radiological reports from pathology/
BAL specimens and HRCT (evaluated by an expertpathologist and an expert radiologist respectively). Due to
funding limitations it was not possible to create a panel of
experts to visit the different hospitals and review each one
of the 967 cases. The working group holds four meetings in
order to standardize the diagnostic criteria. For every test
performed in each one of the participating hospitals there
are internal quality control procedures. In addition,
guidelines for classification were repetitively discussed
during specific sessions organized by the HILD Group. For
the classification of idiopathic interstitial pneumonias’ the
ATS/ERS international multidisciplinary consensus1 was
used. As for sarcoidosis the diagnostic approaches proposed
in the joint statement of the ATS, ERS and the World
Association of Sarcoidosis and Other Granulomatous Disor-
ders (WASOG) were applied.22 ILDs due to neoplastic
diseases, infections or heart diseases were excluded from
the study.
Centers covering about 60% of the Greek adult pop-
ulation (age greater than 15 years), that is 5.6 106
inhabitants, have replied and participated in the study.
The diagnostic process for ILD was the same in all the
centers contacted and the diagnostic algorithm used was
that proposed by the ATS/ERS international multidisci-
plinary consensus.1 Thus, the centers that participated in
the study are probably representative of all the centers
contacted. No major differences in case ascertainment
have been observed among centers.
The study was approved by the Institutional Review
Board of Demokritus University of Thrace.Results
A total of 967 cases have been reported with a small
preponderance of female population (53.6%). The male to
female ratio was 1:1.15. Mean [SE] age of male patients was
58 [0.82] years and that of female 59.3 [0.64] years. Inci-
dence rate is estimated to be 4.63 per 100,000/year and
prevalence 17.3 per 100,000.
Table 1 shows the distribution of prevalent ILD cases and
their prevalence in our population. The most frequent
disease entity is sarcoidosis (34.1%) followed by IIPs
(29.5%). Idiopathic pulmonary fibrosis (IPF) accounted for
about 20% of all ILDs, whilst usual interstitial pneumonia
(UIP) was the most frequent histology among IIPs. The
above-mentioned diseases are followed in decreasing order
by ILD-associated collagen vascular diseases (12.4%), cryp-
togenic organizing pneumonia (5.3%), histiocytosis (3.8%),
and hypersensitivity pneumonitis (2.6%). Unclassified or not
otherwise specified ILDs accounted for the 8.5% of preva-
lent cases.
The incidence of ILDs in our population and the number
(%) of incident cases are shown in Table 2. Among incident
cases, IIPs are the most frequent (32.4%) followed by
sarcoidosis (23.2%).






Sarcoidosis 330 (34.1) 5.89
IIPs 285 (29.5) 5.09
IPFeUIP 189 (19.5) 3.38
NSIP 27 (2.8) 0.48
COP/BOOP 51 (5.3) 0.91
LIP 4 (0.4) 0.07
RBILD 4 (0.4) 0.07
DIP 8 (0.8) 0.14
AIP 2 (0.2) 0.04
Connective tissue diseases 120 (12.4) 2.14
Scleroderma 45 (4.6) 0.80
Rheumatoid arthritis 43 (4.4) 0.77
Dermatomyositis/polymyositis 7 (0.7) 0.13
Systemic lupus erythematosus 7 (0.7) 0.13
Sjo¨gren’s syndrome 5 (0.5) 0.09
Mixed connective tissue disease 2 (0.2) 0.04
Not specified 11 (1.1) 0.20
ILD unclassified, not otherwise
specified
82 (8.5) 1.46
Histiocytosis 37 (3.8) 0.66
Hypersensitivity pneumonitis 25 (2.6) 0.45
Chronic eosinophilic pneumonia 21 (2.2) 0.38
Drug-induced ILD 17 (1.8) 0.30
Occupational 20 (2.0) 0.36
Vasculitides 14 (1.5) 0.25
Lymphangioleiomyomatosis 6 (0.6) 0.11
Alveolar proteinosis 5 (0.5) 0.09
Hemosiderosis 1 (0.1) 0.02
Bronchiolitis obliterans 4 (0.4) 0.07
Total 967 17.3






Sarcoidosis 60 (23.2) 1.07
IIPs 84 (32.4) 1.50
IPFeUIP 52 (20.1) 0.93
NSIP 10 (3.9) 0.18
COP/BOOP 18 (7.0) 0.32
RBILD 1 (0.4) 0.02
DIP 2 (0.8) 0.04
AIP 1 (0.4) 0.02
Connective tissue diseases 30 (11.6) 0.54
Scleroderma 12 (4.6) 0.21
Rheumatoid arthritis 9 (3.5) 0.16
Dermatomyositis/polymyositis 2 (0.8) 0.04
Systemic lupus erythematosous 2 (0.8) 0.04
Sjo¨gren’s syndrome 2 (0.8) 0.04
Mixed connective tissue disease 1 (0.4) 0.02
Not specified 2 (0.8) 0.04
ILD unclassified, not otherwise
specified
40 (15.4) 0.71
Histiocytosis 7 (2.7) 0.13
Hypersensitivity pneumonitis 7 (2.7) 0.13
Chronic eosinophilic pneumonia 7 (2.7) 0.13
Drug-induced ILD 4 (1.5) 0.07
Occupational 8 (3.1) 0.14
Vasculitides 6 (2.3) 0.11
Alveolar proteinosis 1 (0.4) 0.02
Hemosiderosis 1 (0.4) 0.02
Bronchiolitis obliterans 4 (1.5) 0.07
Total 259 4.63
1124 A. Karakatsani et al.Analyses of the procedures used irrespective of contri-
bution to diagnosis (Tables 3 and 4) showed that HRCT was
performed in 87.4% of patients and BAL in 46.1%. In
contrast, only 10.7% of cases had a transbronchial lung
biopsy, whilst surgical lung biopsy was performed either by
thoracotomy (11.4% of cases) or by video-assisted thoracic
surgery (VATS, 6.3% of cases). When focusing on the
procedures used in the diagnosis of IIPs the number of cases
that underwent surgical lung biopsy (thoracotomy or VATS)
rises to 34.1%.
In Table 5 the distribution of ILDs in Greece is compared
to that of other countries revealing interesting similarities
and differences among countries.
Discussion
The current study reports data on almost 1000 ILD cases in
Greece. To the best of our knowledge this is the second
study in the literature to report the results of an ILD
registry conducted by pulmonary medicine centers, after
the new classification of IIPs.1,13 The main findings of our
registry are: (1) sarcoidosis is the most frequent disease,
followed in decreasing order by IPF and connective tissuedisorders, (2) IPF is the most frequent among the group of
IIPs, (3) the estimated annual incidence of ILDs is 4.63 per
100,000 population and the prevalence 17.3 per 100,000.
Almost no epidemiological data are available on
a worldwide basis on the prevalence, incidence or relative
frequency of ILDs, especially after the current ATS/ERS
consensus on the classification of IIPs. Previous studies have
shown that a variety of reasons make the investigation of
the epidemiology of ILDs problematic.1e3 The differences in
results between epidemiological studies may be due to real
differences in incidence, but may also be due to changes in
disease definitions and classifications, differences in the
epidemiological design of studies or even registration bias.9
In general, epidemiological data may be obtained from
different sources or population groups, using different
study designs such as systematic national statistics, pop-
ulation-based data and registries, and large case series of
specific diseases.
The first population-based study of adults, published
before the ATS/ERS consensus reported a prevalence of 81
cases of ILD per 100,000 in males and 67 per 100,000 in
females and an incidence of 32 per 100,000 in males and 26
per 100,000 in females in a limited area, in Bernalillo
County, New Mexico.6 Since then other registries have been
conducted in Italy, Germany, Flanders (Belgium) and more
recently in Spain.7e14
Table 3 Number of procedures irrespective of contribution to diagnosis.a
Surgical biopsy TBB N (%) BB N (%) BAL N (%) HRCT N (%)
OLB N (%) VATS N (%)
Sarcoidosis (NZ 330) 19 (5.8) 14 (4.2) 59 (17.9) 115 (34.8) 176 (53.3) 277 (83.9)
IIPs (NZ 285) 58 (20.4) 39 (13.7) 28 (9.8) 24 (8.4) 157 (55.1) 255 (89.5)
CTD (NZ 120) 7 (5.8) e 2 (1.7) 4 (3.3) 20 (16.7) 113 (94.2)
ILD unclassified (NZ 82) 1 (1.2) 3 (3.7) 2 (2.4) 1 (1.2) 25 (30.5) 74 (90.2)
Histiocytosis (NZ 37) 13 (35.1) 2 (5.4) 1 (2.7) e 16 (43.2) 33 (89.2)
HP (NZ 25) 1 (4.0) 1 (4.0) 3 (12.0) 2 (8.0) 18 (72.0) 21 (84.0)
Chronic eosinophilic
pneumonia (NZ 21)
1 (4.7) e e e 9 (42.9) 17 (81.0)
Drug-induced ILD (NZ 17) e e e e 7 (41.2) 15 (88.2)
Occupational (NZ 20) 1 (5.0) 2 (1.0) 5 (10.0) 1 (5.0) 6 (30) 19 (95.0)
Vasculitides (NZ 14) 6 (42.9) e 1 (7.1) 1 (7.1) 4 (28.6) 11 (78.6)
Alveolar proteinosis (NZ 5) 2 (40.0) e 2 (40.0) e 5 (100) 5 (100)
Hemosiderosis (NZ 1) e e e e 1 (100) 1 (100)
Bronchiolitis obliterans (NZ 4) 1 (20.0) e e e 2 (50.0) 4 (100)
Total (NZ 967) 110 (11.4) 61 (6.3) 103 (10.7) 148 (15.3) 446 (46.1) 845 (87.4)
OLB: open lung biopsy; VATS: video-assisted thoracic surgery; TBB: transbronchial lung biopsy; BB: bronchial biopsy; BAL: bron-
choalveolar lavage; HRCT: high-resolution computed tomography.
a More than one type of biopsy was performed in several patients.
Epidemiology of interstitial lung diseases 1125Our registry, like those in other European countries,7e14
covers patients seen by respiratory medicine centers.
These registries include either incident or prevalent cases,
or even both. Variability of inclusion and exclusion criteria
and the way these criteria were operationally applied
hinders a straightforward comparison between countries.
Moreover, period prevalence data are not strictly compa-
rable. Nevertheless, comparison of Greece with each one of
the countries that have provided prevalence data suggests
significant differences (p-value< 0.001 compared to Flan-
ders and Italy separately). Furthermore, the estimated
annual incidence of ILDs found in our study was 4.63 per
100,000 inhabitants (95% CI from 4.1 105 to 5.2 105),
whilst the recent Xaubet et al.’s registry was 7.6 per
100,000 (95% CI from 6.9 105 to 8.3 105).13 Because of
lack of overlapping the difference is clearly statistical
significant. It should be noted that the incidence in the
Flanders’ registry was 1.0 per 100,000.10 The comparison
between the distribution of ILD in our registry and that ofTable 4 Number of procedures performed in IIP cases, irrespec
Surgical biopsy T
OLB N (%) VATS N (%)
IPFeUIP (NZ 189) 35 (18.5) 25 (13.2) 15
NSIP (NZ 27) 10 (37.0) 5 (18.5) 1
LIP (NZ 4) 2 (50.0) 2 (50.0)
RBILD (NZ 4) 1 (25.0) 1 (25.0)
DIP (NZ 8) 4 (50.0) 2 (25.0) 1
AIP (NZ 2) 1 (50.0) e
BOOP/COP (NZ 51) 5 (9.8) 4 (7.8) 11
Total (NZ 285) 58 (20.4) 39 (13.7) 28
OLB: open lung biopsy; VATS: video-assisted thoracic surgery; TBB: t
lavage; HRCT: high-resolution computed tomography.other registries is presented in Table 5. In all registries the
most frequent diseases were IPF and sarcoidosis.
The relative frequency of IPF (20% of cases) in our study
is similar with the one conducted in Flanders.9 On the
contrary, other registries reported frequencies ranging from
27 to 39%, probably due to inclusion of other IIPs.6e8,10e13
Furthermore, we also found that among incident cases, IIPs
(32.4%) are the most frequent reflecting to some extent
the better diagnostic evaluation of these diseases after the
recent classification.1 In general, few are the data on the
real incidence or prevalence of the other types of IIPs. Our
registry shows that the second most frequent IIP is crypto-
genic organizing pneumonia consisting 5.3% of prevalent
and 7% of incident cases, close enough to the ones reported
from the other registries (ranging from 5 to 10%).
Nonspecific interstitial pneumonia accounted for 2.8% of
IIPs, and the other types for less than 1%. From previous
studies after revaluation of the biopsy findings it has been
estimated that nonspecific interstitial pneumonia accountstive of contribution to diagnosis.
BB N (%) BB N (%) BAL N (%) HRCT N (%)
(7.9) 16 (8.5) 112 (59.3) 168 (88.9)
(3.7) 4 (14.8) 14 (51.9) 25 (92.6)
e e 1 (25.0) 4 (100)
e e e 4 (100)
(12.5) 1 (12.5) 1 (12.5) 8 (100)
e e e 1 (50.0)
(21.6) 3 (5.9) 29 (56.9) 45 (88.2)
(9.8) 24 (8.4) 157 (55.1) 255 (89.5)
ransbronchial biopsy; BB: bronchial biopsy; BAL: bronchoalveolar
Table 5 Comparison of the distribution of ILDs in Greece and other countries.
Greece Spaina Flandersa Germanya Italya N. Mexicoa
Inhabitants 5.6 106 6.7 106 6 106 80 106 57 106 0.48 106
Duration of the registration
(months)
12 12 48 12 30 48
Number of cases 967c 259b 511b 362c 234b 1382c 202b
IPF 189 (19.5%)d 52 (20.1%)d 197 (38.6%)d 72 (19.8%)e 76 (32.5%)e 520 (37.6%)e 63 (31.2%)e
Sarcoidosis 330 (34.1%) 60 (23.2%) 76 (14.9%) 112 (30.9%) 83 (35.5%) 403 (29.2%) 16 (7.9%)
Cryptogenic organizing
pneumonia
51 (5.3%) 18 (7.0%) 53 (10.4%) ef 16 (6.9%) 69 (5.0%) 1 (0.5%)
Connective tissue diseases 120 (12.4%) 30 (11.6%) 51 (9.9%) 27 (7.4%) 5 (2.1%) ef 18 (8.9%)
Hypersensitivity pneumonitis 25 (2.6%) 7 (2.7%) 34 (6.7%) 47 (12.9%) 31 (13.2%) 50 (3.6%) 3 (1.5%)
Chronic eosinophilic
pneumonia
21 (2.2%) 7 (2.7%) 15 (2.9%) 13 (3.5%) 0 91 (6.6%) 0
Drug-induced ILD 17 (1.8%) 4 (1.5%) 17 (3.3%) 12 (3.3%) 6 (2.6%) 23 (1.7%) 7 (3.5%)
Eosinophilic granuloma/
histiocytosis X
37 (3.8%) 7 (2.7%) 15 (2.9%) 13 (3.5%) 0 91 (6.6%) 0
Unclassified/not defined 82 (8.5%) 40 (15.4%) 26 (5.1%) 33 (9.1%) 12 (5.1%) ef 60 (29.7%)
Others 95 (9.8%) 34 (13.1%) 27 (5.3%) 33 (9.1%) 5 (2.1%) 135 (9.7%) 34 (16.8%)
a See Refs. 5,7,9e12.
b Prevalent cases.
c Incident cases.
d Based on the recent classification of IIPs.
e The recent classification of IIPs was not used.
f Not specified.
1126 A. Karakatsani et al.for 14e36% of IIPs.21,23e25 However, in some cases it may be
difficult to distinguish the histological pattern of UIP from
that of fibrotic nonspecific interstitial pneumonia.23
Furthermore, interlobar histological variability is common
in IIPs,26 whilst it has been found that the findings of HRCT
scan may be suggestive of UIP in 32% of patients with
nonspecific interstitial pneumonia.27 Nonetheless, we
found that nonspecific interstitial pneumonia accounted for
2.6% of idiopathic interstitial pneumonias that is very
similar to that of 3.3% in Xaubet et al.’s study,13 in which
the new classification has also been applied.
Previous studies have shown that there is remarkable
diversity of the prevalence of sarcoidosis by area and
ethnicity with a range from less than 1 in Korea 29 to 64 per
100,000 in Sweden.30 One important finding of our registry
is that sarcoidosis was found to be the most frequent
disease in Greece among the prevalent cases (34.1%). Pro-
portionally sarcoidosis is more prevalent in Greece than in
Italy or Spain because overall ILDs are less common in the
former than in the latter countries. Moreover in Greece,
proportionally, the prevalence of sarcoidosis is higher than
the corresponding incidence (the reported annually inci-
dence rate of 1.07 sarcoidosis cases per 100,000 is similar to
1.01 per 100,000 found recently in Japan31 and to 1.36 per
100,000 reported from Catalonia32), because of the very
good prognosis of this disease. It should also be noticed that
in the aforementioned European studies, as well as in our
report, stage I sarcoidosis was included. On the contrary
the lower rate (7.8%) reported from the New Mexico
registry is probably due to inclusion of only stages IIeIV
sarcoidosis.6 The German registry is the only one that
reports the different stages of sarcoidosis separately
concluding that sarcoidosis stage I (37.4%) and stage II (47%)
are the most frequent.7ILD associated with collagen vascular diseases was the
third most frequent disease in our registry accounting for
the 12.4% of prevalent cases. The comparison with other
registries showed that this frequency is very similar to
that of New Mexico6 and the more recent Spanish report
(9.9%).13 Data are not available from Italy, while the
German significantly differs with a reported rate of 2.1%.7
The frequency of hypersensitivity pneumonitis varies
widely in the different registries (Table 5), probably
because its prevalence and incidence in different countries
are influenced by climatic and seasonal conditions, smoking
habits and work practices.28 In our report the frequency of
hypersensitivity pneumonitis was found to be 2.5%. Unfor-
tunately, the etiology has not been included to our ques-
tionnaire, while in the Spanish report, pigeon breeder’s
lung was found to be the most frequent cause.13 The
percentage of unclassified diseases varies greatly in the
different registries (Table 5).
Epidemiologic studies require standardized and detailed
diagnostic criteria. Usually, a stepwise approach is taken in
the diagnosis of ILD, while the recent ERS/ATS classification
strongly recommends a multidisciplinary evaluation
between pneumonologists, pathologists and radiologists in
order to obtain the correct diagnosis.1 In our cohort,
analyses of the procedures used to establish the diagnosis
(Tables 3 and 4) showed that HRCT was performed in 87.4%
of patients and BAL in 46.1%. The frequency of the appli-
cation of these techniques is lower than that of the Xaubet
et al.’s registry (Table 5). On the contrary, both studies
have used the recently established criteria for IIPs.
Surgical lung biopsy was performed in 17.7% of ILD cases
but in 34.1% of IIP cases. These numbers are similar to those









Date of birth:……………….(day/month/year) 
Diagnosis:…………………………………………………………………………………………. 
Date of diagnosis:…………………………… 
Diagnostic procedures: 
Open lung biopsy  Yes  No 
VATS    Yes  No 
Bronchial biopsy  Yes  No 
Transbronchial biopsy Yes  No 
BAL    Yes  No 
HRCT    Yes  No 
Other: 
Mediastinoscopy    Other biopsy (skin, muscle, etc, please define)….………   
 Ga scanning    SACE  Serology (please define)…………………………   
The diagnosis was based on: (please comment)……………………………………………………. 
………………………………………………………………………………………………………. 
The patient is alive:  Yes  No 
If not, 
Date of death…………………………………… 
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1128 A. Karakatsani et al.Our findings suggest that in Greece sarcoidosis as well as
IPF has a low incidence and prevalence. Although based on
population seen by respiratory medicine centers, thus
a possible selection bias can not be excluded, current
experience indicates that almost all patients with ILD are
attended by pneumonologists.
In conclusion, these data suggest that sarcoidosis and IPF
are the most frequent ILDs in our population. In comparison
with the few previous reports, interesting dissimilarities
have been observed. Further studies are warranted to
investigate the epidemiology of ILDs in various countries in
order to compare any differences and chronological trends.
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